GLP-1 and metabolic
New GLP-1 Drugs 2026: Approved and Late-Stage Incretin Compounds
AM
· 10 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 8 sections
As of October 2026, five incretin-class compounds covered here have an approval somewhere: semaglutide, tirzepatide, orforglipron (first approved in the United States in April 2026), mazdutide (China, 2025) and ecnoglutide (China, 2026). Late-stage candidates include retatrutide, CagriSema and survodutide, all with published phase 3 results, and amycretin, MariTide, eloralintide and pemvidutide, with phase 3 trials under way. This page is a dated snapshot. Every row cites its source, and the table will go out of date.

How to read this page
This is a snapshot taken on 25 October 2026. Drug approvals, trial results and company decisions in this field change month by month, and some of what is below will be wrong within a year. Each row gives the source it rests on: a PubMed record for approvals and trial results, or a ClinicalTrials.gov record for trials that have not reported. Where a fact could not be confirmed from those sources, it is left out rather than guessed.
"Approved" here means approved by at least one regulator for at least one use. It does not mean approved in Canada, and it does not mean approved for weight management. Canadian status is checked separately in Health Canada's Drug Product Database, and the article on generic semaglutide in Canada explains why authorisation attaches to a specific product, not a molecule.
The receptor names in the tables are explained in the GLP-1, GIP and glucagon receptor guide and, for the amylin compounds, in amylin receptors explained.
Which incretin-class drugs are approved?
| Compound | Targets | Sponsor | Approvals confirmed | Source |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Novo Nordisk | United States, Puerto Rico and Canada for type 2 diabetes by early 2018; authorised in Canada for weight management as Wegovy | Dhillon 2018 (PMID 29363040) |
| Tirzepatide | GIP and GLP-1 receptor agonist | Eli Lilly | First approved in the United States in May 2022 for type 2 diabetes; authorised in Canada | Syed 2022 (PMID 35830001) |
| Orforglipron | GLP-1 receptor agonist; non-peptide small molecule | Eli Lilly | United States, April 2026, for long-term weight management; under review in the EU, Japan, and in Canada for type 2 diabetes | Shirley 2026 (PMID 42479349) |
| Mazdutide | GLP-1 and glucagon receptor agonist | Innovent Biologics with Eli Lilly | China: weight management in June 2025, type 2 diabetes in September 2025 | Shirley 2025 (PMID 41028652) |
| Ecnoglutide | cAMP-biased GLP-1 receptor agonist | Sciwind Biosciences | China: type 2 diabetes in January 2026, weight management in March 2026 | Shirley 2026 (PMID 42412371) |
A few notes on the rows.
Semaglutide and tirzepatide are the reference drugs against which everything else is measured. Their Canadian authorisations are covered in tirzepatide vs semaglutide. The 2018 profile of semaglutide records its early approvals in the United States, Puerto Rico and Canada for type 2 diabetes.
Orforglipron is the first non-peptide GLP-1 receptor agonist in this table. It is a small molecule rather than a peptide, which changes how it is made and handled but not the receptor it acts on. Its profile records that it had been submitted for review in Canada for type 2 diabetes; no Canadian decision was confirmed for this article.
Mazdutide and ecnoglutide are approved only in China, as far as this article could confirm. Their phase 3 trials were run in Chinese populations, which matters when setting their numbers beside Western trials. Mazdutide's trials are covered in detail in the mazdutide article. Ecnoglutide is described as cAMP-biased, meaning it was designed to favour one signalling pathway downstream of the GLP-1 receptor.
Older GLP-1 receptor agonists, such as liraglutide and dulaglutide, are approved and widely used but are not new, and are not tabulated here.
Which compounds are in late-stage trials?
| Compound | Targets | Sponsor | Stage, October 2026 | Source |
|---|---|---|---|---|
| Retatrutide | GIP, GLP-1 and glucagon receptor agonist | Eli Lilly | Phase 3 (TRIUMPH) results publishing; approved nowhere | Jastreboff 2026 (PMID 42814954) |
| CagriSema | Semaglutide plus cagrilintide, an amylin analogue; two peptides | Novo Nordisk | Phase 3 (REDEFINE, REIMAGINE) published; no approval confirmed | Garvey 2025 (PMID 40544433) |
| Survodutide | GLP-1 and glucagon receptor agonist | Boehringer Ingelheim | Phase 3 (SYNCHRONIZE) published in obesity and fatty liver disease; approved nowhere | le Roux 2026 (PMID 42253238) |
| Amycretin (zenagamtide) | One molecule acting at GLP-1, amylin and calcitonin receptors | Novo Nordisk | Phase 2 published; phase 3 (AMAZE) recruiting | Mora 2026 (PMID 42532080); NCT07339423 |
| MariTide (maridebart cafraglutide) | Antibody blocking the GIP receptor, carrying two GLP-1 agonist peptides | Amgen | Phase 2 published; phase 3 (MARITIME) under way | Jastreboff 2025 (PMID 40549887); NCT06858839 |
| Eloralintide | Selective amylin receptor agonist | Eli Lilly | Phase 2 published; phase 3 (ENLIGHTEN) recruiting | Billings 2025 (PMID 41207310); NCT07321886 |
| Pemvidutide | GLP-1 and glucagon receptor agonist | Altimmune | Phase 2b in MASH published; phase 3 in MASH recruiting | Noureddin 2025 (PMID 41237796); NCT07795164 |
What the late-stage trials have shown so far
Retatrutide. In TRIUMPH-1, 2,339 adults with obesity and no diabetes were randomised for 80 weeks. Mean weight change ran from −17.6% to −25.0% across the retatrutide groups against −3.9% on placebo. Further phase 3 trials, including TRIUMPH-3 in obesity with cardiovascular disease (NCT05882045), are listed as completed but had not all published by late October 2026. The TRIUMPH article covers the programme.
CagriSema. In REDEFINE 1, in 3,417 adults with obesity and no diabetes, weight change at 68 weeks was −20.4% against −3.0% on placebo. Gastrointestinal events affected 79.6% against 39.9%. The full programme, including the diabetes trials, is in CagriSema results.
Survodutide. In SYNCHRONIZE-1, 725 adults with obesity and no diabetes had weight change of −12.2% and −13.0% at 76 weeks on two dose levels against −5.4% on placebo. Its cardiovascular outcomes trial had not published. See survodutide.
Amycretin. Phase 2 trials in type 2 diabetes met their HbA1c endpoints. The weight figures most often quoted come from a small, single-site phase 1b/2a study with many withdrawals. See amycretin.
MariTide. In the 52-week phase 2 trial, adults with obesity had weight change of −12.3% to −16.2% against −2.5% on placebo. Why it blocks the GIP receptor while tirzepatide activates it is covered in MariTide.
Eloralintide. In its 48-week phase 2 trial, 263 adults with obesity or overweight and no diabetes had weight change of −9% to −20% across the doses studied, against −0.4% on placebo; nausea and fatigue were the most common adverse events. See eloralintide's phase 2 data.
Pemvidutide. In the phase 2b IMPACT trial in MASH with fibrosis, it met the endpoint of MASH resolution without fibrosis worsening at 24 weeks but not the fibrosis-improvement endpoint. Its development has focused on liver disease. Why glucagon is added at all is in glucagon receptor agonists explained.
Why the numbers cannot be ranked
It is tempting to sort the late-stage table by the largest weight-loss figure. That would be a mistake, for reasons that apply to every row:
- Durations differ. The figures above were measured at 48, 52, 68, 76 and 80 weeks.
- Estimands differ. Some trials count everyone randomised regardless of whether they stayed on treatment; others report what happened in people who did. The same drug can produce figures several points apart depending on which is used, as survodutide's fatty liver trial shows.
- Populations differ. In every programme above that tested both groups, people with type 2 diabetes lost less weight than people without it, and Chinese, Japanese and Western trial populations differ in baseline BMI.
- Placebo groups differ. A placebo group that loses 5% narrows the treatment difference; one that gains weight widens it.
Only head-to-head randomised trials answer which drug produces more weight loss. Several are registered, including CagriSema against tirzepatide and amycretin against semaglutide, and few have reported. The questions to ask of any trial are set out in the study design guide.
What else is there to watch?
Outcome trials. Weight and HbA1c are surrogate endpoints. The trials that decide whether these drugs reduce heart attacks, strokes, heart failure or liver failure are larger and slower. Among them are SYNCHRONIZE-CVOT for survodutide (NCT06077864), MARITIME-CV for MariTide (NCT07037433), AMBIENCE for amycretin (NCT07861100) and REDEFINE 3 for CagriSema. Tirzepatide's completed outcome data are covered in tirzepatide cardiovascular outcomes.
Combinations. Eli Lilly has registered AMPLIFY trials combining eloralintide with tirzepatide (NCT07881432), listed as not yet recruiting.
Regulatory decisions. Orforglipron's reviews in the EU, Japan and Canada were pending at the time of its approval profile. Survodutide, retatrutide and CagriSema all have phase 3 results, which is the point at which companies usually file; no filing or decision for any of them could be confirmed for this article.
What this page is not
None of the investigational compounds above is authorised in Canada. A product sold under one of these names outside a pharmacy has none of the manufacturing controls, prescribing or monitoring of the trial drug or the licensed medicine, a point covered in Health Canada's warnings about unauthorized GLP-1 products.
Supplied here for laboratory use: Tirzepatide and Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
These are laboratory reagents. They are not the licensed medicine or the investigational product, and no trial result on this page describes them. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
What new GLP-1 drugs were approved in 2026? Among compounds this article could confirm, orforglipron, a non-peptide GLP-1 receptor agonist from Eli Lilly, was first approved in the United States in April 2026 for long-term weight management. Ecnoglutide was approved in China in January 2026 for type 2 diabetes and in March 2026 for weight management.
Is retatrutide approved yet? No. Retatrutide had published phase 3 results by October 2026, including TRIUMPH-1 and TRIUMPH-2, but no regulator had authorised it for any use. No regulatory filing or decision could be confirmed for this article. Published phase 3 results are evidence for a regulator to review, not an approval.
Which new GLP-1 drug causes the most weight loss? That cannot be answered from this table. The trials differ in duration, population, estimand and placebo response, so their figures are not comparable. Only head-to-head trials can rank drugs, and most of those registered for these compounds had not reported by October 2026.
Are any of these new drugs available in Canada? Semaglutide and tirzepatide are authorised in Canada. Orforglipron had been submitted for review in Canada for type 2 diabetes, according to its mid-2026 approval profile, but no decision was confirmed. The other compounds in the tables are not authorised in Canada.
How often will this page be updated? This is a dated snapshot from 25 October 2026 and will go stale. Approvals, filings and trial results in this field change quickly. Check the cited PubMed and ClinicalTrials.gov records, and Health Canada's Drug Product Database for Canadian status, before relying on any row.
Selected Research References
- Dhillon S. Semaglutide: First Global Approval. Drugs. 2018;78:275-284. pubmed.ncbi.nlm.nih.gov/29363040
- Syed YY. Tirzepatide: First Approval. Drugs. 2022;82:1213-1220. pubmed.ncbi.nlm.nih.gov/35830001
- Shirley M. Orforglipron: First Approval. Drugs. 2026;86:1735-1745. pubmed.ncbi.nlm.nih.gov/42479349
- Shirley M. Mazdutide: First Approval. Drugs. 2025;85:1621-1627. pubmed.ncbi.nlm.nih.gov/41028652
- Shirley M. Ecnoglutide: First Approvals. Drugs. 2026;86:1563-1570. pubmed.ncbi.nlm.nih.gov/42412371
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635-647. pubmed.ncbi.nlm.nih.gov/40544433
- le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. New England Journal of Medicine. 2026;395:776-787. pubmed.ncbi.nlm.nih.gov/42253238
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. New England Journal of Medicine. 2025;393:843-857. pubmed.ncbi.nlm.nih.gov/40549887
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406:2631-2643. pubmed.ncbi.nlm.nih.gov/41207310
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
